Log in

NASDAQ:TTOOT2 Biosystems Stock Price, Forecast & News

+0.40 (+23.53 %)
(As of 08/10/2020 04:00 PM ET)
Today's Range
Now: $2.10
50-Day Range
MA: $1.49
52-Week Range
Now: $2.10
Volume39.78 million shs
Average Volume11.54 million shs
Market Capitalization$251.03 million
P/E RatioN/A
Dividend YieldN/A
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
T2 Biosystems logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:TTOO



Sales & Book Value

Annual Sales$8.34 million
Book Value($0.73) per share


Net Income$-59,010,000.00
Net Margins-645.05%


Market Cap$251.03 million
Next Earnings Date8/11/2020 (Confirmed)
+0.40 (+23.53 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

How has T2 Biosystems' stock been impacted by COVID-19 (Coronavirus)?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TTOO shares have increased by 324.2% and is now trading at $2.10.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of T2 Biosystems?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for T2 Biosystems

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for T2 Biosystems

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) announced its quarterly earnings data on Tuesday, May, 5th. The medical equipment provider reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.06. The medical equipment provider earned $2.55 million during the quarter.
View T2 Biosystems' earnings history

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its second quarter 2020 After-Hours earnings guidance on Tuesday, June, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.4-2.6 million, compared to the consensus revenue estimate of $2.44 million.

What price target have analysts set for TTOO?

5 analysts have issued 12-month target prices for T2 Biosystems' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate T2 Biosystems' stock price to reach $4.00 in the next year. This suggests a possible upside of 90.5% from the stock's current price.
View analysts' price targets for T2 Biosystems

Has T2 Biosystems been receiving favorable news coverage?

News coverage about TTOO stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. T2 Biosystems earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about T2 Biosystems

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 4,120,000 shares, an increase of 16.4% from the December 31st total of 3,540,000 shares. Based on an average daily volume of 623,800 shares, the short-interest ratio is presently 6.6 days. Currently, 10.5% of the shares of the stock are sold short.
View T2 Biosystems' Short Interest

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Heat Biologics (HTBX), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Biocept (BIOC), VBI Vaccines (VBIV), NVIDIA (NVDA) and Verastem (VSTM).

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Prof. Michael J. Cima, Co-Founder & Independent Director (Age 60, Pay $62.5k)
  • Mr. Alec Barclay, Sr. VP of Operations (Age 39, Pay $477.4k)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 41, Pay $473.93k)
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 56)
  • Dr. Tyler E. Jacks, Co-Founder (Age 59)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different retail and institutional investors. Top institutional investors include Ironwood Financial llc (0.05%), HighTower Advisors LLC (0.04%) and McAdam LLC (0.02%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems

Which major investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Ironwood Financial llc. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, David B Elsbree, John Mcdonough, and Thomas J Lowery.
View insider buying and selling activity for T2 Biosystems

Which major investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including McAdam LLC, and HighTower Advisors LLC.
View insider buying and selling activity for T2 Biosystems

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $2.10.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $251.03 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 151 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.